Related Experiment Video

Updated: Jun 3, 2026

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
08:54

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds

Published on: February 14, 2018

Safety of micafungin in pediatric clinical trials

Antonio C Arrieta1, Philip Maddison, Andreas H Groll

  • 1Division of Infectious Disease, Children's Hospital of Orange County, Orange, CA, USA. AArrieta@choc.org

The Pediatric Infectious Disease Journal
|March 8, 2011
PubMed

Insights

Micafungin is a safe antifungal medication for children, including premature infants and those with serious health conditions. Adverse events were rare and rarely led to treatment discontinuation.

Area of Science:

  • Pediatric Infectious Diseases
  • Clinical Pharmacology
  • Drug Safety and Pharmacovigilance

Background:

  • Pediatric invasive fungal infections (IFIs) pose significant risks to vulnerable young patients.
  • Antifungal safety is paramount in pediatric populations with complex medical histories.
  • Micafungin is an echinocandin antifungal agent with potential use in children.

Purpose of the Study:

  • To evaluate the safety and tolerability of micafungin in pediatric patients (<16 years).
  • To assess adverse events (AEs) in children receiving micafungin for various fungal infections or prophylaxis.
  • To analyze safety data across different age groups, including neonates and premature infants.

Main Methods:

  • Pooled safety data from 296 pediatric patients across 6 international clinical trials.
  • Inclusion of patients with invasive aspergillosis, candidiasis, and those receiving antifungal prophylaxis.
  • Adverse events were systematically recorded and analyzed for causality, severity, and relationship to study drug.

Main Results:

  • Micafungin was administered to 296 pediatric patients (mean age 6.5 years), including 66 infants <1 year and 38 premature infants.
  • Common underlying conditions included hematopoietic stem cell transplantation (33.8%) and hematologic malignancy (29.1%).
  • Overall, 93.2% of patients experienced AEs, with 26.7% possibly related to micafungin. Serious AEs occurred in 34% of patients, with 4.7% possibly related to the drug. Discontinuation due to AEs was low (2.4%).

Conclusions:

  • Micafungin demonstrated a favorable safety profile in pediatric patients across all age groups, including those with critical underlying conditions.
  • The drug was generally well-tolerated, with a low incidence of drug-related adverse events leading to treatment discontinuation.
  • Micafungin is a viable and safe treatment option for invasive fungal infections in children.
Abstract

More Related Videos

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance08:45

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance

Published on: December 28, 2017

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus12:29

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus

Published on: April 19, 2017

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Fungal Phylum Microsporidia01:28

Fungal Phylum Microsporidia

Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...